Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis

Journal of Neuroimmunology

Volumn 93, Issue 1-2, 1999, Pages 8-14

  Rudick, Richard A ^a   Cookfair, Diane L ^b   Simonian, Nancy A ^c   Ransohoff, Richard M ^a   Richert, John R ^d   Jacobs, Lawrence D ^b   Herndon, Robert M ^e   Salazar, Andres M ^f   Fischer, Jill S ^a   Granger, Carl V ^b   Goodkin, Donald E ^g   Simon, Jack H ^h   Bartoszak, David M ^f   Bourdette, Dennis N ⁱ   Braiman, Jonathan ^f   Brownscheidle, Carol M ^b   Coats, Michael E ^f   Cohan, Stanley L ^d   Dougherty, David S ^f   Kinkel, Revere P ^a   Mass, Michele K ^d   Munchsauer, Frederick E ^b   O'Reilly, Kathy ^b   Priore, Roger L ^b   Pullicino, Patrick M ^b   Scherokman, Barbara J ^j   Wende, Karl ^b   Weinstock Guttman, Bianca ^a   Whitham, Ruth H ⁱ   more..

^a Mellen Center for Multiple Sclerosis Treatment and Research   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c BIOGEN   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e LEGACY GOOD SAMARITAN HOSPITAL   (United States)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j KAISER PERMANENTE   (United States)

more..

Author keywords

Cerebrospinal fluid; Controlled clinical trials; CSF free kappa light chains; CSF IgG index; Interferon; Interferon beta; Multiple sclerosis; Oligoclonal bands

Indexed keywords

BETA1A INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; PLACEBO;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

ADJUVANTS, IMMUNOLOGIC; ADULT; CEREBROSPINAL FLUID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULINS; INTERFERON-BETA; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; RECURRENCE;

EID: 0032943375     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00174-X     Document Type: Article

References (23)

1. Andersson M., Alvarez-Cermeno J., Bernardi G., Cogato I., Fredman P., Frederiksen J., Fredrikson S., Gallo P., Grimaldi L.M., Gronning M.et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report [Review] [50 refs]. J. Neurol. Neurosurg. Psychiatry. 57:1994;897-902.
2. Calabresi P.A., Tranquill L.R., Dambrosia J.M., Stone L., Maloni H., Bash C.N., Frank J.A., McFarland H.F. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann. Neurol. 41:1997;669-674.
3. Cassatella M.A., Meda L., Bonora S., Ceska M., Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J. Exp. Med. 178:1998;2207-2211.
4. Garrone P., Galibert L., Rousset F., Fu S.M., Banchereau J. Regulatory effects of prostaglandin E2 on the growth and differentiation of human B lymphocytes activated through their CD40 antigen. J. Immunol. 152:1994;4284-4290.
5. Hershey L.A., Trotter J.L. The use and abuse of the cerebrospinal fluid IgG profile in the adult: a practical evaluation. Ann. Neurol. 8:1980;426-434.
6. Hommes O.R., Lamers K.J.B., Van Geel W. Intrathecal IgG synthesis and IgG index after intensive and chronic immunosuppressive treatment of multiple sclerosis. Ann. New York Acad. Sci. 436:1984;410-417.
7. Jacobs L., Cookfair D.L., Rudick R.A.et al. A phase III trial of intramuscular recombinant beta interferon as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis. 1:1995;118-135.
8. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E. 3rd, Priore R.L., Pullicino P.M., Scherokman B.J., Whitham R.H.et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:1996;285-294.
9. Jacobs, L., Munschauer, F., 1992. Treatment of multiple sclerosis with interferons. In: Rudick, R.A., Goodkin, D.E. (Eds.), Treatment of Multiple Sclerosis: Trial Design, Results and Future Perspectives. Springer-Verlag, London, pp. 233-250.
10. Leppert D., Waubant E., Burk M.R., Oksenbert J.R., Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1997;846-852.
11. Link H., Müller R. Immunoglobulins in multiple sclerosis and infections of the nervous system. Arch. Neurol. 25:1971;326-344.
12. Link H., Tibbling G. Principles of albumin and IgG analyses in neurological disorders: III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand. J. Clin. Lab. Invest. 37:1977;397-401.
13. Liorente L., Zou W., Levy Y., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., Morel-Fourrier B., Brouet J.C., Alarcon-Segovia D., Gelanaud P. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med. 181:1995;839-844.
14. Marcelletti J.F., Katz D.H. IL-10 stimulates murine antigen-driven antibody responses in vitro by regulating helper cell subset participation. Cell. Immunol. 167:1996;86-98.
15. Olsson T. Multiple sclerosis: cerebrospinal fluid [Review] [25 refs]. Ann. Neurol. 36(Suppl.):1994;S100-2.
16. Pirttila T., Nurmikko T. CSF oligoclonal bands, MRI, and the diagnosis of multiple sclerosis. Acta Neurol. Scand. 92:1995;468-471.
17. Rudick R.A., French C.A., Breton D., Williams G.W. Relative diagnostic value of cerebrospinal fluid kappa chains in MS: comparison with other immunoglobulin tests. Neurology. 39:1989;964-968.
18. Rudick R.A., Ransohoff R.M., Lee J.-C., Peppler R., Yu M., Mathisen P.M., Tuohy V. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 50:1998;1294-1300.
19. Stanescu G.L., Swick A.R., Tuohy V.K., Rudick R.A. Sensitive competitive-binding ELISAs for quantifying free kappa and lambda light chains in cerebrospinal fluid. J. Clin. Lab. Anal. 5:1991;206-211.
20. Stuve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., Yong W.V. Interferon-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40:1997;853-863.
21. The IFNB Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;655-661.
22. Tourtellotte W.W., Baumhefner R.W., Potvin A.R., Ma B.I., Potvin J.H., Mendez M., Syndulko K., Mendez M. Multiple sclerosis de novo CNS IgG synthesis: effect of ACTH and corticosteroids. Neurology. 30:1980;1155-1162.
23. Tripp C.S., Wolf S.F., Unanue E.R. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc. Natl. Acad. Sci. 90:1993;3725-3729.